SuspendedNot Applicable

Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

Stopped: Study completed Phase 1 before funding ended.

United States817 participantsStarted 2021-11-20

Plain-language summary

This study will disseminate five surveys collecting individual's attitudes and experiences during buprenorphine treatment for Opioid Use Disorder during the COVID-19 pandemic.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants must be 18 years of age or older. * Participants report currently having a legal prescription for buprenorphine for opioid use disorder. * Participants must have a past or present opioid use disorder. * Participants must currently reside in the state of Massachusetts. * Participants must be able to comprehend the English language. Exclusion Criteria: * Unable to complete an online survey. * Unable to complete a verification step that ensures bots are not used to complete survey. * Complete a survey with no variation suggesting they did not read the survey.

What they're measuring

Patient's Experiences with Office-Based Opioid Treatment

Timeframe: Day 1

Reasons for Abstaining from Opioids Questionnaire

Timeframe: Day 1

Patients' Attitudes Toward the Use of Cannabis During Office-Based Opioid Treatment

Timeframe: Day 1

Patients' Attitudes Toward the Use of Cigarettes/E-Cigarettes During Office-Based Opioid Treatment

Timeframe: Day 1

Patients' Attitudes Toward and Experiences with the Use of Benzodiazepines during Office-Based Opioid Treatment

Timeframe: Day 1

Trial details

NCT IDNCT05121428

SponsorCambridge Health Alliance

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-03-20

View on ClinicalTrials.gov More Opioid-use Disorder trials